Edition:
United States

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

77.66USD
23 May 2018
Change (% chg)

$1.05 (+1.37%)
Prev Close
$76.61
Open
$76.94
Day's High
$77.71
Day's Low
$76.53
Volume
2,329,739
Avg. Vol
2,478,944
52-wk High
$147.13
52-wk Low
$74.14

Latest Key Developments (Source: Significant Developments)

Prothena Announces Reorganization To Focus Resources On Advancing Neuroscience Pipeline
Thursday, 24 May 2018 09:00am EDT 

May 24 (Reuters) - Prothena Corporation PLC ::PROTHENA ANNOUNCES REORGANIZATION TO FOCUS RESOURCES ON ADVANCING NEUROSCIENCE PIPELINE.PROTHENA CORPORATION PLC - INITIATED A REORGANIZATION TO ALIGN ITS RESOURCES ON ADVANCING ITS BROAD NEUROSCIENCE PIPELINE.PROTHENA CORPORATION PLC - FOLLOWING REORGANIZATION EXPECTS ITS WORKFORCE TO BE APPROXIMATELY 63 POSITIONS..PROTHENA CORPORATION PLC - COMPANY IS REVISING ITS FULL YEAR 2018 FINANCIAL GUIDANCE.PROTHENA CORPORATION PLC - EXPECTS 2018 NET CASH BURN FROM OPERATING & INVESTING ACTIVITIES TO BE $40 TO $50 MILLION.PROTHENA CORPORATION PLC - AS A RESULT OF DISCONTINUATION OF NEOD001 DEVELOPMENT PROGRAM, WILL REDUCE WORKFORCE BY ABOUT 57 PERCENT.PROTHENA - ESTIMATED 2018 NET LOSS INCLUDES $80 TO $85 MILLION OF OPERATING EXPENSES ASSOCIATED WITH NEOD001 AND REORGANIZATION.PROTHENA - REORGANIZATION INCLUDES ONGOING CLINICAL-STAGE PROGRAMS FOR PRX002/RG7935, PROPRIETARY PROGRAM PRX004 DISCOVERY-STAGE PIPELINE.PROTHENA - REORGANIZATION INCLUDES DISCOVERY-STAGE PIPELINE, 3 PROGRAMS BEING ADVANCED UNDER COLLABORATION WITH CELGENE.  Full Article

Celgene Corp Announces Additional $3 Bln Share Repurchase Authorization; Plans To Execute A $2 Bln Accelerated Share Repurchase Program
Thursday, 24 May 2018 07:30am EDT 

May 24 (Reuters) - Celgene Corp ::CELGENE CORPORATION ANNOUNCES ADDITIONAL $3 BILLION SHARE REPURCHASE AUTHORIZATION AND PLANS TO EXECUTE A $2 BILLION ACCELERATED SHARE REPURCHASE PROGRAM.CELGENE CORPORATION ANNOUNCES ADDITIONAL $3 BILLION SHARE REPURCHASE AUTHORIZATION AND PLANS TO EXECUTE A $2 BILLION ACCELERATED SHARE REPURCHASE PROGRAM.CELGENE CORP - PLANS TO EXECUTE A $2 BILLION ACCELERATED SHARE REPURCHASE PROGRAM.CELGENE CORP - PLANNED ASR WILL UTILIZE PART OF EXISTING BOARD AUTHORIZED SHARE REPURCHASE PROGRAM AS WELL AS PART OF NEW AUTHORIZATION.CELGENE CORP - REMAINING AUTHORIZATION WILL BE USED IN CONTINUING OPEN-ENDED PROGRAM EFFECTIVE IMMEDIATELY.  Full Article

Evotec And Celgene Enter Into Strategic Oncology Partnership
Monday, 21 May 2018 03:31pm EDT 

May 21 (Reuters) - Evotec Ag ::DGAP-ADHOC: EVOTEC AND CELGENE ENTER INTO STRATEGIC ONCOLOGY PARTNERSHIP.UNDER TERMS OF AGREEMENT, EVOTEC WILL RECEIVE AN UPFRONT PAYMENT OF $65 MILLION.CELGENE RECEIVES EXCLUSIVE OPT-IN RIGHTS TO LICENSE WORLDWIDE RIGHTS TO ALL PROGRAMMES DEVELOPED WITHIN THIS COLLABORATION.EVOTEC MAY BE ELIGIBLE TO RECEIVE SIGNIFICANT MILESTONE PAYMENTS AS WELL AS TIERED ROYALTIES ON EACH LICENSED PROGRAMME.  Full Article

Zymeworks And Celgene Expand Bispecific Antibody Collaboration
Monday, 23 Apr 2018 04:05pm EDT 

April 23 (Reuters) - Celgene Corp ::ZYMEWORKS AND CELGENE EXPAND BISPECIFIC ANTIBODY COLLABORATION.ZYMEWORKS INC - CELGENE CORP EXERCISED RIGHT TO EXPAND DEAL FOR COMMERCIALIZATION OF BISPECIFIC ANTIBODY THERAPEUTICS USING CO'S AZYMETRIC PLATFORM.ZYMEWORKS INC - ZYMEWORKS WILL RECEIVE AN EXPANSION FEE.ZYMEWORKS INC - IN TOTAL, ZYMEWORKS IS NOW ELIGIBLE TO RECEIVE UP TO $1.64 BILLION IN FUTURE PAYMENTS FOR ENTIRE COLLABORATION.ZYMEWORKS INC - CELGENE HAS EXERCISED ITS RIGHT TO INCREASE NUMBER OF POTENTIAL PRODUCTS IT CAN DEVELOP AND COMMERCIALIZE FROM EIGHT TO TEN.  Full Article

Celgene Announces Changes To Its Board Of Directors
Thursday, 19 Apr 2018 07:48am EDT 

April 19 (Reuters) - Celgene Corp ::CELGENE CORPORATION ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS.CELGENE CORP - JUNO THERAPEUTICS CO-FOUNDER AND FORMER CEO HANS BISHOP ELECTED TO BOARD OF DIRECTORS.CELGENE CORP - GILLA KAPLAN RETIRING FROM BOARD OF DIRECTORS.CELGENE CORP - PATRICIA HEMINGWAY HALL ELECTED TO BOARD OF DIRECTORS.CELGENE CORP - GILLA KAPLAN WILL NOT STAND FOR REELECTION AT UPCOMING ANNUAL MEETING OF STOCKHOLDERS.  Full Article

Celgene Corp Announces Departure Of President And COO Scott A. Smith
Monday, 2 Apr 2018 04:31pm EDT 

April 2 (Reuters) - Celgene Corp ::ORATION ANNOUNCES DEPARTURE OF PRESIDENT AND CHIEF OPERATING OFFICER SCOTT A. SMITH.SMITH'S PRIMARY RESPONSIBILITIES WILL BE ASSUMED BY CHAIRMAN AND CHIEF EXECUTIVE OFFICER MARK J. ALLES.  Full Article

Abide And Celgene Enter Worldwide License Agreement For ABX-1772
Wednesday, 28 Mar 2018 07:07am EDT 

March 28 (Reuters) - Celgene Corp ::ABIDE AND CELGENE ENTER WORLDWIDE LICENSE AGREEMENT FOR ABX-1772.‍ABIDE THERAPEUTICS SAYS GRANTED CELGENE AN EXCLUSIVE WORLDWIDE LICENSE FOR ABX-1772, A PRECLINICAL DRUG CANDIDATE DISCOVERED BY ABIDE​.‍ABIDE THERAPEUTICS SAYS ABIDE RECEIVED UNDISCLOSED PAYMENT AND WILL BE ENTITLED TO CERTAIN MILESTONE PAYMENTS AND ROYALTIES ON COMMERCIAL SALES​.‍ABIDE THERAPEUTICS SAYS ABIDE HAS REGAINED EX-US RIGHTS TO ABX-1431 FROM CELGENE​.  Full Article

Amunix Operating Says Has Entered Into A Licensing Agreement With Celgene
Tuesday, 20 Feb 2018 07:00am EST 

Feb 20 (Reuters) - Celgene Corp ::AMUNIX OPERATING SAYS HAS ENTERED INTO A LICENSING AGREEMENT WITH CELGENE.  Full Article

Celgene Announces Retirement Of Executive Chairman Bob Hugin
Monday, 29 Jan 2018 10:54am EST 

Jan 29 (Reuters) - Celgene Corp ::CELGENE ANNOUNCES RETIREMENT OF EXECUTIVE CHAIRMAN BOB HUGIN AND APPOINTMENT OF CEO MARK ALLES AS CHAIRMAN OF THE BOARD OF DIRECTORS.SAYS ‍CEO MARK ALLES APPOINTED TO ADDITIONAL ROLE OF CHAIRMAN OF BOARD OF DIRECTORS​.SAYS EXECUTIVE CHAIRMAN BOB HUGIN TO RETIRE AND STEP DOWN FROM CELGENE'S BOARD OF DIRECTORS EFFECTIVE FEBRUARY 5, 2018.  Full Article

Juno Therapeutics Says If Deal Terminated By Co Or Celgene, Fee Of $300 Mln May Be Payable By Co To Celgene
Monday, 22 Jan 2018 08:44am EST 

Jan 22 (Reuters) - Celgene Corp ::JUNO THERAPEUTICS SAYS IF DEAL TERMINATED BY CO OR CELGENE UPON SPECIFIED CONDITIONS, FEE OF $300 MILLION MAY BE PAYABLE BY CO TO CELGENE - SEC FILING.JUNO THERAPEUTICS SAYS DEAL AGREEMENT PROVIDES CELGENE TO HAVE TO PAY CO REVERSE TERMINATION FEE OF $600 MILLION IF DEAL TERMINATED UNDER SOME CONDITIONS.  Full Article

BRIEF-Evotec And Celgene Enter Into Strategic Oncology Partnership

* DGAP-ADHOC: EVOTEC AND CELGENE ENTER INTO STRATEGIC ONCOLOGY PARTNERSHIP